Trial
NCT04274166
Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Wake Forest University Health Sciences
Collaborators
Novartis
Condition
Pyoderma Gangrenosum
Intervention
secukinumab 150 mg (2 injections per dose
Why stopped
Contracting never completed, closed the IRB
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-05-28